Science & Safety
Science & Safety: Mechanisms, Eligibility and Traceability
We document each therapy by mechanism, current evidence and clear limits, never as a sales catalog. Advanced therapy is eligibility-gated and applied only on a prepared terrain.
How the therapies work
Mesenchymal stem cells
Biological modulators: secretion of trophic factors, anti-inflammatory cytokines and extracellular vesicles. Documented by mechanism, current evidence and clear limits, applied only per RBRI™ eligibility.
Exosomes
Cell-derived signaling vesicles used as a support modality. We explain how they differ from whole-cell therapy and where the evidence currently stands.
Ozone autohemotherapy
Primary Terrain Reset tool for modulating oxidative and inflammatory load prior to advanced therapy.
Differentiated IV therapy (incl. NAD+)
Signal Optimization support; documented by rationale and evidence, not marketed as a cure.
Evidence-based peptides
Adjunctive signaling support within Phase II, within physician-directed limits.
Eligibility, quality control & traceability
Candidacy is set at the Regenerative Medical Review via the The RBRI™. Biological products are handled under defined quality-control and traceability standards, reviewed with each patient before therapy. Access to advanced cellular medicine, where relevant, is discussed individually and never listed in public price comparisons or first-contact materials.
Our Laboratory Partner
Processed under international quality standards
Our cellular products are processed by a certified cellular-therapy laboratory integrated within a network of partner laboratories across the Americas, including Chile, Argentina, and Costa Rica, among others. The laboratory operates under the most relevant international quality standards and complies with all applicable regulatory requirements for cellular therapy, ensuring traceability, viability, and safety of every batch.
Frequently asked questions
Are stem cell treatments safe?
Regenerative therapies carry real risks and are not appropriate for everyone. Candidacy is assessed at the Regenerative Medical Review, therapy is physician-directed, and advanced biological therapy is applied only on a prepared terrain and per the RBRI™ readiness score.
Am I eligible for treatment?
Eligibility is determined at the Regenerative Medical Review using the RBRI™. Not every patient is a candidate; when that is the case, we say so.
What is the difference between exosomes and stem cells?
Stem cells are whole living cells with immunomodulatory and trophic activity; exosomes are cell-derived signaling vesicles used as a support modality. They are documented separately by mechanism, evidence and limits.
How are cells sourced and quality-controlled?
Biological products are handled under defined quality-control and traceability standards. Sourcing, characterization and release criteria are reviewed with each patient before any therapy.
How long is the program and travel?
Base program duration and any suggested extension are set after the Review, with logistics coordinated by our concierge team for international patients.
Content on this page is educational and is not a treatment offer or medical advice. Regenerative therapies are eligibility-gated and physician-directed. Statements about therapies reflect current understanding and are subject to change as evidence evolves.
Begin with a medical evaluation, not a booking.
The Regenerative Medical Review is the eligibility-gated entry point to every program.
Request Medical Review